Cibus, Inc. entered into investment agreement with AstraZeneca PLC to subscribe for 16,000,000 ordinary shares at a price of $5 per share for gross proceeds of $80 million on November 01, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.59 USD | -.--% | +2.93% | -10.44% |
09/05 | Cibus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
09/05 | Transcript : Cibus, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.44% | 41Cr | |
+11.29% | 23TCr | |
+8.76% | 19TCr | |
+12.90% | 14TCr | |
+25.95% | 11TCr | |
+0.15% | 6.36TCr | |
+5.62% | 5.13TCr | |
+11.08% | 5.1TCr | |
+6.28% | 4.33TCr | |
+4.80% | 3.7TCr |
- Stock Market
- Equities
- CLXT Stock
- News CALYXTPAR
- Cibus, Inc. announced that it expects to receive $80 million in funding